华恒生物
(688639)
| 流通市值：62.07亿 | | | 总市值：67.87亿 |
| 流通股本：2.28亿 | | | 总股本：2.50亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 445,305,816.8 | 393,542,579.06 | 370,916,208.82 | 352,984,098.78 |
| 应收票据及应收账款 | 270,178,635.12 | 302,479,563.29 | 305,144,998.32 | 304,166,933.11 |
| 其中：应收票据 | 39,225,232.98 | 31,818,446.54 | 47,235,903.15 | 58,418,991.08 |
| 应收账款 | 230,953,402.14 | 270,661,116.75 | 257,909,095.17 | 245,747,942.03 |
| 应收款项融资 | 30,597,870.27 | 26,105,569.77 | 12,060,205.86 | 14,261,767.71 |
| 预付款项 | 37,952,781.71 | 31,138,601.24 | 52,127,044.04 | 29,223,417.35 |
| 其他应收款合计 | 9,083,376.51 | 12,175,199.82 | 17,024,844.28 | 10,465,105.69 |
| 存货 | 354,258,578.97 | 263,638,391.49 | 323,961,981.21 | 226,464,157.69 |
| 其他流动资产 | 92,593,551.29 | 151,982,689.5 | 127,078,861.64 | 112,480,925.69 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,239,970,610.67 | 1,181,062,594.17 | 1,208,314,144.17 | 1,050,046,406.02 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 121,543,144.73 | 120,448,953.04 | 118,500,033.33 | 112,400,033.33 |
| 固定资产 | 1,261,173,601.08 | 1,178,948,510.95 | 1,178,043,248.21 | 1,091,691,993.45 |
| 在建工程 | 1,832,371,837.41 | 1,789,385,019.48 | 1,678,588,538.34 | 1,528,529,944.18 |
| 无形资产 | 101,134,772.61 | 84,730,650.91 | 85,503,156.22 | 86,275,591.03 |
| 递延所得税资产 | 65,131,773.52 | 61,810,304.13 | 52,372,462.03 | 49,394,898.42 |
| 其他非流动资产 | 82,914,337.14 | 76,131,143.55 | 65,900,475.72 | 51,899,226.87 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,464,269,466.49 | 3,311,454,582.06 | 3,178,907,913.85 | 2,920,191,687.28 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 4,704,240,077.16 | 4,492,517,176.23 | 4,387,222,058.02 | 3,970,238,093.3 |
| 流动负债: | | | | |
| 短期借款 | 1,346,423,032.9 | 1,165,984,280.6 | 1,177,117,518.26 | 915,121,195.63 |
| 应付票据及应付账款 | 523,131,961.99 | 576,512,558.79 | 614,453,322.22 | 589,006,238.71 |
| 应付账款 | 523,131,961.99 | 576,512,558.79 | 614,453,322.22 | 589,006,238.71 |
| 合同负债 | 17,026,904.91 | 12,317,834.11 | 22,009,175.52 | 12,767,817.17 |
| 应付职工薪酬 | 24,716,815.81 | 20,773,893.49 | 16,023,213.11 | 31,071,567.28 |
| 应交税费 | 3,356,207.09 | 6,745,987.68 | 20,482,061.62 | 31,640,091.06 |
| 其他应付款合计 | 28,814,307.49 | 169,993,991.79 | 29,961,275.62 | 28,393,143.62 |
| 应付股利 | - | 141,582,343.5 | - | - |
| 一年内到期的非流动负债 | 89,503,615.3 | 52,966,073.52 | 35,910,696.59 | 26,598,872.89 |
| 其他流动负债 | 19,092,817.53 | 14,832,924.65 | 26,881,852.58 | 41,879,676.1 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 2,052,065,663.02 | 2,020,127,544.63 | 1,942,839,115.52 | 1,676,478,602.46 |
| 非流动负债: | | | | |
| 长期借款 | 607,587,606.99 | 458,001,709.74 | 375,963,095.73 | 304,933,359.33 |
| 递延收益 | 93,458,451.38 | 90,401,039.06 | 90,076,426.74 | 91,526,814.42 |
| 递延所得税负债 | 95,741,590.88 | 90,505,982.25 | 76,574,641.92 | 71,638,541.91 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 796,787,649.25 | 638,908,731.05 | 542,614,164.39 | 468,098,715.66 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 2,848,853,312.27 | 2,659,036,275.68 | 2,485,453,279.91 | 2,144,577,318.12 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 228,601,487 | 157,810,315 | 157,540,180 | 157,540,180 |
| 资本公积 | 544,280,999.47 | 612,885,746.47 | 605,650,777.77 | 603,464,352.77 |
| 减:库存股 | 53,612,725.12 | 53,612,725.12 | 57,212,725.12 | 45,242,637.58 |
| 其他综合收益 | 525,367.87 | 810,535.26 | 744,681.34 | 721,619.52 |
| 盈余公积 | 55,632,195.85 | 55,632,195.85 | 55,632,195.85 | 55,632,195.85 |
| 未分配利润 | 1,083,166,825.58 | 1,062,980,853.59 | 1,141,429,576.37 | 1,054,855,465.25 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,858,594,150.65 | 1,836,506,921.05 | 1,903,784,686.21 | 1,826,971,175.81 |
| 少数股东权益 | -3,207,385.76 | -3,026,020.5 | -2,015,908.1 | -1,310,400.63 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,855,386,764.89 | 1,833,480,900.55 | 1,901,768,778.11 | 1,825,660,775.18 |
| 负债和股东权益合计 | 4,704,240,077.16 | 4,492,517,176.23 | 4,387,222,058.02 | 3,970,238,093.3 |
| 公告日期 | 2024-10-29 | 2024-08-28 | 2024-04-22 | 2024-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |